Commentary: cardioprotective aspirin and gastroduodenal ulcers

Affiliations

Comment

James M Scheiman. Aliment Pharmacol Ther. 2020 Jan.

. 2020 Jan;51(1):203.

doi: 10.1111/apt.15532.

¹ Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA.

No abstract available

Comment on

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin.
Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ. Yeomans ND, et al. Aliment Pharmacol Ther. 2005 Nov 1;22(9):795-801. doi: 10.1111/j.1365-2036.2005.02649.x. Aliment Pharmacol Ther. 2005. PMID: 16225488

1. Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393:2155-2167.
1. Lavie CJ, Howden CW, Scheiman J, Tursi J. Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention. Curr Probl Cardiol. 2017;42:146-164.
1. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795-801.
1. Scheiman J, Devereaux P, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in cardiovascular risk patients treated with low-dose acetylsalicylic acid at risk for ulcer development: a randomized, controlled trial (OBERON). Heart. 2011;97:797-802.
1. Bhatt D, Scheiman JM, Abraham N, et al. ACCF/ACG/AHA clinical expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118:1894-1909.